Comparative In Vitro activity of quinupristin/dalfopristin and seven other antimicrobials against methicillin-susceptible and methicillin-resistant nosocomial Staphylococcus aureus bloodstream isolates

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 544-546

  Nikolaidis, Paul ^a,b   Metallidis, S ^a   Katikaridou, E ^b   Chatzidimitriou, M ^b   Kollaras, P ^a   Tsona, A ^a   Koumentaki, E ^a   Tourkantonis, A ^a  

^a Laboratory of Infectious Diseases   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Glycopeptides; Methicillin resistant staphylococci; Quinupristin dalfopristin; Staphylococcus aureus; Streptogramin

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; OXACILLIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD FLOW; CONTROLLED STUDY; GRAM STAINING; HOSPITAL INFECTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 0036972390     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.544     Document Type: Article

References (11)

1. Bryson HM, Spencer CM. Quinupristin-dalfopristin. Drugs 1996; 52: 406-415.
2. Bouanchaud DH. In-vitro and in-vivo synergistic activity and fractional inhibitory concentration (FIC) of the components of the semisynthetic streptogramin, PR 59500. J Antimicrob Chemother 1992; 30, Supplement A: 95-99.
3. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs 1996; 51 Supplement 1: 6-12.
4. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infection in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91 supplement 3B: 86S-89S.
5. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 supplement A: 19-24.
6. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of infection in Intensive Care (EPIC) study. JAMA 1995; 274(8): 639-44.
7. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Contr Hosp Epidem 1992; 13: 700-5.
8. Marinus A, Schouten MA, Hoogkamp-Korstanje JAA. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates. J Antimicrob Chemother 1997; 40: 213-9.
9. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (PR 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31 (3): 437-51.
10. Low DE, Nadler HL. A review of in-vitro activity of quinupristin-dalfopristin against methicillin-susceptible and resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Supplement A: 53-58.
11. Luh KT, Hsueh PR, Teng LJ, et al. Quinopristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000; 44(12): 3374-80.